Investor company presentation February 2026 Forward-looking statements The information in this presentation contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "intend", "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements ...

Sustainability Meeting 2025 Astellas Pharma Inc. February 26, 2026 ことを確認してください。 ©2026 ASTELLAS PHARMA INC. AND ITS AFFILIATES. アステラス 製薬の画像は、 MediaValetから入手で きます(ガイダンススラ イドを参照)。 スライドマスターファイ ルに機密保持または著作 権表示 に関する正しい フッターを追加している Cautionary Statement Regarding Forward-Looking Information In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma ...

Core Viewpoint - ClaimsFiler is reminding investors of the deadline to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics, related to undisclosed material information during the Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Corcept and its executives failed to disclose material information, violating federal securities laws during the Class Period from October 31, 2024, to December 30, 2025 [3]. - The complaint specifically mentions that Corcept misled investors regarding the likelihood of FDA approval for its product candidate, relacorilant, following its New Drug Application submission [4]. - Following the disclosure of a Complete Response Letter from the FDA on December 31, 2025, which indicated that additional evidence of effectiveness was needed, Corcept's share price fell by $35.40, or 50.4%, from $70.20 to $34.80 [4]. Group 2: Legal and Investor Support - The case is officially titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, No. 26-cv-01525 [5]. - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information access and case evaluations [6].

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. RBC Capital Initiates Pfizer (PFE) with $25 Target, Warns of Structural Revenue Headwinds Photo by Dan Dennis on Unsplash On February 25, RBC Capital initiated coverage of Pfizer Inc. (NYSE:PFE) with an Underperform rating and a $25 price target. The firm said its outlook reflects an “insurmountable” $15B-$20B revenue decline expected through 2030, with limited visibility into new products that ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Case Allegations - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the approval status of its Pivotal Study by the FDA [5] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [5] - The lawsuit asserts that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Affordable Dividend Stocks to Buy According to Analysts. RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects On February 25, RBC Capital initiated coverage of Merck & Co., Inc. (NYSE:MRK) with an Outperform rating and a $142 price target. The firm believes investor interest in the stock could continue, supported by upcoming product launches and Phase 3 trial results that may lead to higher earnings estimates. The analyst a ...

Core Insights - MindRank has initiated the Phase III clinical trial for MDR-001, an AI-designed oral GLP-1 receptor agonist aimed at treating obesity and type 2 diabetes in China [1][2] - The trial, named MOBILE, will involve approximately 750 patients across 50 clinical centers, assessing the long-term efficacy and safety of MDR-001 [2] - MDR-001 has shown promising results in a Phase IIb trial, demonstrating clinically meaningful efficacy and favorable tolerability [3] Company Overview - MindRank is a clinical-stage biotechnology company that leverages AI for drug discovery, focusing on "hard-to-drug" targets to enhance the efficiency and success rate of new drug development [9] - The company utilizes its proprietary AI platform, Molecule Pro™, which integrates various scientific disciplines to optimize drug discovery processes [7][9] Technology and Innovation - The Molecule Pro™ platform employs advanced AI techniques, including deep learning and generative AI, to facilitate drug discovery and optimize lead compounds [7][8] - The platform's capabilities include predicting drug safety and optimizing molecular design to improve the chances of successful drug development [8] Development Milestones - The development of MDR-001 progressed from project initiation to U.S. IND clearance in 19 months and reached Phase III within approximately 4.5 years [4] - The dosing of the first patient in Phase III is considered a significant milestone for both MDR-001 and AI-driven drug development [6]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Hims & Hers Health, Inc. ("Hims†or the "Company†) (NYSE: HIMS) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click here to participate. On February 7, 2026, The New York Times reported that the Company would stop selling its version of Wegovy, a popular weight loss drug by competitor Novo Nordisk. A former FDA commissione ...

Core Insights - Genomma Lab Internacional reported a challenging year in 2025, with like-for-like sales declining by -4.3% due to a weak summer beverage season and a softer consumption environment in Mexico [1] - The company achieved a year-end EBITDA margin of 23.4%, demonstrating strong business fundamentals despite topline pressure [1] - Genomma Lab anticipates that growth initiatives will gain traction in the second half of 2026, supporting a recovery in operational leverage [1] Financial Performance Summary - Q4 2025 net sales decreased by -13.9% to MXN 4,017 million, while full-year net sales fell by -5.7% to MXN 17,541 million [1] - Gross profit for Q4 2025 was MXN 2,449 million, a decline of -16.7% year-over-year, with a full-year gross profit of MXN 11,022 million, down -7.6% [1] - Net income from continuous operations decreased by -23.1% for the full year 2025, totaling MXN 1,607 million, and declined by -13.0% in Q4 2025 to MXN 319 million [1] Operational Highlights - The company unlocked MXN 1.1 billion in productivity savings to reinvest in growth initiatives, including product innovation and distribution expansion [1] - The cash-conversion cycle remained healthy at 107 days, indicating effective management of working capital [1] - Despite a -2.2% decline in Mexico sell-out during Q4, underlying consumer demand was confirmed to be resilient [1]

Novo Nordisk (NYSE:NVO), which develops and markets diabetes and obesity treatments, closed Wednesday at $38.16, down 1.11%. The stock slipped as investors weighed a large Vivtex partnership while watching how competition and margins shape Novo’s obesity and diabetes franchise. Trading volume reached 54.7 million shares, about 141% above its three-month average of 22.7 million shares. Novo Nordisk IPO'd in 1981 and has grown 23,750% since going public. How the markets moved today The S&P 500 added 0.82% ...